Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

SAGE launches two new journals in Drug Safety, Hematology

SAGE Expands Therapeutic Advances series by launching two new journals in Drug Safety and Hematology. SAGE has extended its suite of Therapeutic Advances journals with the launch of a further two titles: Therapeutic Advances in Drug Safety, and Therapeutic Advances in Hematology.

3 Dec 2010

Xencor, MorphoSys initiate XmAb5574 Phase 1 study in CLL

Xencor, Inc. and MorphoSys AG announced today that they have initiated Phase 1 testing for XmAb®5574 (MOR208), and the first patient has been dosed. XmAb5574 (MOR208) is a potent monoclonal anti-CD19 antibody to which MorphoSys recently gained worldwide access via an exclusive license and collaboration agreement with Xencor.

2 Dec 2010

New clue in leukemia mystery

There is new hope for people with acute myelogenous leukemia (AML), a fast-growing cancer of the blood and bone marrow. Research led by Weill Cornell Medical College and published today in the online edition of the journal Cancer Cell reveals a surprising and unexpected cancer-causing mechanism. The investigators discovered that newly identified mutant enzymes in AML create a chemical poison to cause leukemia. Their findings should prove useful in treating patients by providing a molecular target against which to develop new drugs against one subset of AML as well as other cancers.

2 Dec 2010

Pfizer to present data on hematology portfolio at ASH Annual Meeting

Pfizer said today that new data on investigational compounds in its hematology portfolio will be presented at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, December 4-7.

1 Dec 2010

ASH to host annual meeting for blood disorders at Orange Convention Center

The American Society of Hematology (ASH) will host its 52nd annual meeting at the Orange County Convention Center in Orlando, FL, December 4-7. More than 20,000 attendees are expected for this event, which will highlight emerging research trends in the diagnosis, treatment, and understanding of blood disorders.

1 Dec 2010

Initial data from resminostat Phase II Hodgkin Lymphoma trial to be presented at 52nd ASH

4SC, a drug discovery and development company focused on autoimmune and cancer indications, today announced that initial safety and efficacy data from its ongoing Phase II Study with resminostat, a pan-Histone Deacetylase (HDAC) Inhibitor, in relapsed/refractory Hodgkin Lymphoma (HL) patients after high dose chemotherapy and autologous hematopoietic stem cell transplantation will be presented at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida, USA.

1 Dec 2010

Results of pixantrone phase III trial for non-Hodgkin's lymphoma to be presented at Hematology Meeting

Cell Therapeutics, Inc. announced today that Ruth Pettengell, M.D. of St. George's Hospital, University of London, the lead investigator for the PIX 301 EXTEND trial will present end of study results for the pixantrone phase III trial in relapsed/refractory aggressive non-Hodgkin's lymphoma at the 52nd Annual Meeting of the American Society of Hematology on Sunday, December 5, 2010 in Orlando, Florida.

1 Dec 2010

Elorac's naloxone lotion receives FDA Orphan Drug Designation for pruritus associated with mycosis fungoides

Elorac, Inc., a rapidly growing specialty pharmaceutical company focused on the treatment of dermatological disorders announced that it has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for its naloxone lotion for the topical treatment of pruritus accompanying cutaneous t-cell lymphoma (CTCL, also known as mycosis fungoides).

1 Dec 2010

Golimumab with methotrexate improves markers of inflammation and structural damage in RA patients

Magnetic resonance imaging (MRI) analyses from two Phase 3 clinical trials showed that once every four week subcutaneous injections of golimumab 50 mg plus methotrexate resulted in statistically significant improvements in markers of inflammation and structural damage in patients with active rheumatoid arthritis (RA) compared with placebo plus methotrexate.

30 Nov 2010

Overexpression of microRNA 125b can cause leukemia: Research

Whitehead Institute researchers have shown in mouse models that overexpression of the microRNA 125b (miR-125b) can independently cause leukemia and accelerate the disease's progression. Their results are published in this week's online edition of the Proceedings of the National Academy of Sciences (PNAS).

30 Nov 2010

Calistoga to feature data on CAL-101 inhibitor for hematologic malignancies at ASH Annual Meeting

Calistoga Pharmaceuticals, Inc., the leader in the development of delta-isoform-selective phosphatidylinositol 3-kinase (PI3K-delta) inhibitors for the treatment of cancer and inflammatory diseases, today announced the upcoming presentation of clinical and preclinical results supporting the clinical benefit of CAL-101, an oral, PI3K-delta inhibitor, in the treatment of patients with hematologic malignancies.

30 Nov 2010

Hana Biosciences to present Marqibo data for acute lymphoblastic leukemia at ASH Annual Meeting

Hana Biosciences, a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that data regarding Marqibo for treatment of adults with relapsed/refractory acute lymphoblastic leukemia (ALL) will be the subject of two presentations at the 2010 Annual Meeting and Exposition of the American Society of Hematology (ASH) being held in Orlando, Florida from December 4-7, 2010.

30 Nov 2010

Accentia enters strategic agreement with Baxter to purchase Cytoxan drug

Accentia Biopharmaceuticals, Inc. today announced a strategic agreement with Baxter Healthcare Corporation to provide Accentia with the exclusive, worldwide right to purchase Baxter's cyclophosphamide, which is marketed under the brand name Cytoxan, for the treatment of designated autoimmune diseases including multiple sclerosis.

29 Nov 2010

JAK3 pathway highlighted as leukemia target

An intriguing study published in Expert Review of Anticancer Therapy has revealed that the signaling protein JAK3 represents a viable target in the treatment of a broad range of B-lineage cancers, including acute lymphoblastic leukemia (ALL).

28 Nov 2010

Phase 3 trial: TYSABRI improves vision in MS patients

Results recently presented from a study of multiple sclerosis (MS) patients taking TYSABRI (natalizumab) are supported by a Canadian woman's improved vision since starting the therapy.

25 Nov 2010

Elbit Imaging closes transaction with Enter

Elbit Imaging Ltd. announced today that, further to its announcement dated September 13, 2010, it has successfully closed the transaction with Enter Holdings 1 Ltd. and Enter's controlling shareholders.

25 Nov 2010

Collective efforts in transplantation reduces risk of treatment-related complications in blood cancer

A decade of refinements in marrow and stem cell transplantation to treat blood cancers significantly reduced the risk of treatment-related complications and death, according to an institutional self-analysis of transplant-patient outcomes conducted at Fred Hutchinson Cancer Research Center.

25 Nov 2010

Researchers identify trigger mechanism for quality control checkpoint in cell division process

Researchers from Huntsman Cancer Institute (HCI) at the University of Utah report that they have identified a previously undiscovered trigger mechanism for a quality control checkpoint at the very end of the cell division process in a paper to be published in the November 29 issue of The Journal of Cell Biology and online today.

23 Nov 2010

Researchers reconstitute first step of break repair in cancerous cells

What prompts normal cells to transform themselves into cancerous cells. Researchers from Texas institutions, including the UT Health Science Center San Antonio, have identified factors in the very first step of the process and reconstituted this first step in the test tube. The latter accomplishment was reported Sunday [Nov. 21] in the top-tier journal Nature Structural & Molecular Biology.

22 Nov 2010

Lotsa Helping Hands' new feature connects community members to healthcare nonprofit organizations

Lotsa Helping Hands, the leading provider of a web-based caregiving coordination service, today announces a new feature that connects its community members to trusted resources from many of the nation's leading healthcare nonprofit organizations.

20 Nov 2010

Lymphoma News and Research

Further Reading

SAGE launches two new journals in Drug Safety, Hematology

Xencor, MorphoSys initiate XmAb5574 Phase 1 study in CLL

New clue in leukemia mystery

Pfizer to present data on hematology portfolio at ASH Annual Meeting

ASH to host annual meeting for blood disorders at Orange Convention Center

Initial data from resminostat Phase II Hodgkin Lymphoma trial to be presented at 52nd ASH

Results of pixantrone phase III trial for non-Hodgkin's lymphoma to be presented at Hematology Meeting

Elorac's naloxone lotion receives FDA Orphan Drug Designation for pruritus associated with mycosis fungoides

Golimumab with methotrexate improves markers of inflammation and structural damage in RA patients

Overexpression of microRNA 125b can cause leukemia: Research

Calistoga to feature data on CAL-101 inhibitor for hematologic malignancies at ASH Annual Meeting

Hana Biosciences to present Marqibo data for acute lymphoblastic leukemia at ASH Annual Meeting

Accentia enters strategic agreement with Baxter to purchase Cytoxan drug

JAK3 pathway highlighted as leukemia target

Phase 3 trial: TYSABRI improves vision in MS patients

Elbit Imaging closes transaction with Enter

Collective efforts in transplantation reduces risk of treatment-related complications in blood cancer

Researchers identify trigger mechanism for quality control checkpoint in cell division process

Researchers reconstitute first step of break repair in cancerous cells

Lotsa Helping Hands' new feature connects community members to healthcare nonprofit organizations

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News